AbbVie is a trade on whether Skyrizi and Rinvoq keep outgrowing the Humira hole. The general method lives in the stock courses. The story with AbbVie is the immunology handoff.
The Cliff Already Happened
AbbVie is a biopharma whose defining event of the 2020s was the Humira loss of exclusivity — and the question of whether Skyrizi and Rinvoq, plus Allergan aesthetics, actually replaced the cash. That replacement is a number, not a vibe. If your ABBV thesis is “they survived Humira,” you still need to say what you own now: immunology growth, Botox/aesthetics, or a pipeline the market has not priced.
Education only. Not medical advice. Size ABBV as a high-yield healthcare name with payer and LOE-gap risk.
1. Humira, Allergan and the handoff
Spun from Abbott in 2013 so the pharma P&L could live on its own. Humira was the reason the spin worked and the reason the 2023-2025 market argued. Allergan (2020) brought Botox, CoolSculpting-class aesthetics, and a different cyclicality (discretionary procedures). Two histories, one ticker.
Immunology switching — from a TNF to IL-23/JAK-class products — is clinical and commercial. Payer step-edits can slow a “better drug.” Better in a trial is not automatic share. Watch net price and scripts, not just labels.
Aesthetics is GDP- and wealth-sensitive in a way Humira never was. A recession that barely nicks immunology can punch Botox. Do not average those elasticities.
2. What the modern company sells
Immunology (Skyrizi, Rinvoq, leftover Humira), aesthetics (Botox and the Allergan book), neuroscience, oncology, eye care. Mix will keep moving as Humira erodes internationally on a different clock than the U.S.
Gross-to-net in U.S. pharma is the dark matter. List-price headlines are not net. Rebate and IRA-class negotiations sit on every immunology share.
Competition is Amgen, J&J, Novartis-class immunology, and a long list of dermatology and GI challengers. A franchise can stay huge and still lose the scarcity premium. Merck is heading toward the cliff AbbVie already went over, so the two make a useful before-and-after pair.
3. Why it still compounds — and what stops it
Clinical data, device/aesthetics brand, and a commercial machine built to replace Humira are the moat. Patent time on the replacement products is the new timer. Timers always win eventually.
What stops compounding: a safety label on a JAK or IL-23, a payer squeeze that caps net price, or an aesthetics recession on top of a pipeline miss.
ABBV can grow the new immunology pair and still de-rate if you paid for a second Humira instead of a diversified pharma.
4. How traders actually use the ticker
ABBV gaps on scripts, guidance, and dividend coverage talk. Implied moves are real for a “yield” name. Size as pharma, not as a bond. Use the position size calculator before a quarterly print, because the immunology numbers move this stock more than the dividend does. A big print on the stock scanner on a quiet day usually means pipeline or pricing news, so read the headline before reacting.
Example only: $56,000 in the account, $560 at risk and a stop $9 under a $195 entry gives about 62 shares. Write the level into your trading plan before earnings, not after, and check it against the risk management rules if the setup is fuzzy.
Pairs vs LLY only if you have an immunology-versus-incretin view. Those are different objects.
5. Mistakes, limits, takeaways
Mistakes: “post-cliff = cheap” without a mix model; ignoring aesthetics cyclicality; treating the dividend as a put. The segment table in the 10-K shows Humira erosion against Skyrizi and Rinvoq growth; the financial statements course shows how to read it, and what stock trading is covers the basics.
Not medical advice. Labels and payer rules change. Educational only.
Before you trade it
- Replacement products are the object now that the old cliff is behind it.
- Aesthetics is cyclical.
- Net price is what counts, after rebates come off the list price.
- Size for a label or payer gap.
The Humira cliff is behind AbbVie; whether the next one is managed as well is the open question. Educational only. Not tax, legal, or a recommendation to buy, sell, or hold ABBV.